Vascular endothelial growth factor-targeted therapy in renal cell carcinoma : Current status and future directionsRINI, Brian I.Clinical cancer research. 2007, Vol 13, Num 4, pp 1098-1106, issn 1078-0432, 9 p.Article

Molecularly targeted therapy in renal cell carcinoma : where do we go from here?RINI, Brian I.Expert review of anticancer therapy. 2006, Vol 6, Num 12, pp 1753-1760, issn 1473-7140, 8 p.Article

Metastatic Renal Cell Carcinoma: Many Treatment Options, One PatientRINI, Brian I.Journal of clinical oncology. 2009, Vol 27, Num 19, pp 3225-3234, issn 0732-183X, 10 p.Article

Temsirolimus, an Inhibitor of Mammalian Target of RapamycinRINI, Brian I.Clinical cancer research. 2008, Vol 14, Num 5, pp 1286-1290, issn 1078-0432, 5 p.Article

New approaches in advanced renal cell carcinomaRINI, Brian I.Urologic oncology. 2005, Vol 23, Num 1, pp 65-66, issn 1078-1439, 2 p.Article

New Strategies in Kidney Cancer: Therapeutic Advances through Understanding the Molecular Basis of Response and ResistanceRINI, Brian I.Clinical cancer research (Print). 2010, Vol 16, Num 5, pp 1348-1354, issn 1078-0432, 7 p.Article

Clinical effect and future considerations for molecularly-targeted therapy in renal cell carcinoma : Kidney Cancer: Opportunity for Disease Specific Targeted TherapyRINI, Brian I; FLAHERTY, Keith.Urologic oncology. 2008, Vol 26, Num 5, pp 543-549, issn 1078-1439, 7 p.Conference Paper

Castration-Resistant Prostate Cancer: Many Treatments, Many Options, Many Challenges AheadGARCIA, Jorge A; RINI, Brian I.Cancer. 2012, Vol 118, Num 10, pp 2583-2593, issn 0008-543X, 11 p.Article

Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinomaRINI, Brian I; SMALL, Eric J.Journal of clinical oncology. 2005, Vol 23, Num 5, pp 1028-1043, issn 0732-183X, 16 p.Article

Renal cell carcinomaRINI, Brian I; CAMPBELL, Steven C; ESCUDIER, Bernard et al.Lancet (British edition). 2009, Vol 373, Num 9669, pp 1119-1132, issn 0140-6736, 14 p.Article

Immunotherapy for metastatic renal cell carcinoma : RCCMCDERMOTT, David F; RINI, Brian I.BJU international (Papier). 2007, Vol 99, Num 5, pp 1282-1288, issn 1464-4096, 7 p., bArticle

The evolving role of surgery for advanced renal cell carcinoma in the era of molecular targeted therapyRINI, Brian I; CAMPBELL, Steven C.The Journal of urology. 2007, Vol 177, Num 6, pp 1978-1984, issn 0022-5347, 7 p.Article

A Phase I trial of fixed dose rate gemcitabine and capecitabine in metastatic renal cell carcinomaRINI, Brian I; WEINBERG, Vivian; SMALL, Eric J et al.Cancer. 2005, Vol 103, Num 3, pp 553-558, issn 0008-543X, 6 p.Article

Clinical trials in patients with biochemically relapsed prostate cancerLIN, Amy M; RINI, Brian I; SMALL, Eric J et al.BJU international (Papier). 2006, Vol 97, Num 5, pp 905-910, issn 1464-4096, 6 p.Article

Sorafenib : In advanced renal cancer. CommentaryMCKEAGE, Kate; WAGSTAFF, Antona J; STAEHLER, Michael et al.Drugs (Basel). 2007, Vol 67, Num 3, pp 475-485, issn 0012-6667, 11 p.Article

The intersection of sunitinib with the immunosuppressive microenvironment of renal cell carcinoma : implications for future therapeuticsSALAS, Renée N; FINKE, James H; RINI, Brian I et al.Targeted oncology. 2007, Vol 2, Num 4, pp 225-234, issn 1776-2596, 10 p.Article

Prostate-specific antigen kinetics as a measure of the biologic effect of granulocyte-macrophage colony-stimulating factor in patients with serologic progression of prostate cancerRINI, Brian I; WEINBERG, Vivian; BOK, Robert et al.Journal of clinical oncology. 2003, Vol 21, Num 1, pp 99-105, issn 0732-183X, 7 p.Article

The potential for prostate cancer immunotherapyRINI, Brian I; SMALL, Eric J.Critical reviews in oncology/hematology. 2003, Vol 46, pp S117-S125, issn 1040-8428, SUPConference Paper

Flt-3 ligand and sequential FL/interleukin-2 in patients with metastatic renal carcinoma: Clinical and biologic activityRINI, Brian I; PAINTAL, Ajit; VOGELZANG, Nicholas J et al.Journal of immunotherapy (1997). 2002, Vol 25, Num 3, pp 269-277, issn 1524-9557Article

Clinical and immunological characteristics of patients with serologic progression of prostate cancer achieving long-term disease control with granulocyte-macrophage colony-stimulating factorRINI, Brian I; FONG, Lawrence; WEINBERG, Vivian et al.The Journal of urology. 2006, Vol 175, Num 6, pp 2087-2091, issn 0022-5347, 5 p.Article

Prostate cancer immunology : Biology, therapeutics, and challengesWEBSTER, W. Scott; SMALL, Eric J; RINI, Brian I et al.Journal of clinical oncology. 2005, Vol 23, Num 32, pp 8262-8269, issn 0732-183X, 8 p.Article

Association of VEGF and VEGFR2 Single Nucleotide Polymorphisms with Hypertension and Clinical Outcome in Metastatic Clear Cell Renal Cell Carcinoma Patients Treated With SunitinibKIM, Jenny J; VAZIRI, Susan A. J; RINI, Brian I et al.Cancer. 2012, Vol 118, Num 7, pp 1946-1954, issn 0008-543X, 9 p.Article

Cessation of Vascular Endothelial Growth Factor―Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma: Feasibility and Clinical OutcomeSADEGHI, Sarmad; ALBIGES, Laurence; WOOD, Laura S et al.Cancer. 2012, Vol 118, Num 13, pp 3277-3282, issn 0008-543X, 6 p.Article

The Impact of Kidney Function on the Outcome of Metastatic Renal Cell Carcinoma Patients Treated With Vascular Endothelial Growth Factor-Targeted TherapyMACFARLANE, Robyn; HENG, Daniel Y. C; WANLING XIE et al.Cancer. 2012, Vol 118, Num 2, pp 365-370, issn 0008-543X, 6 p.Article

Progression-Free Survival as a Predictor of Overall Survival in Metastatic Renal Cell Carcinoma Treated With Contemporary Targeted TherapyHENG, Daniel Y. C; WANLING XIE; CHOUEIRI, Toni K et al.Cancer. 2011, Vol 117, Num 12, pp 2637-2642, issn 0008-543X, 6 p.Article